Javascript must be enabled to continue!
Roles of CCL2 Gene Expression in Peripheral Blood of Patients with Kidney Disease
View through CrossRef
Chronic kidney disease (CKD), acute kidney injury (AKI), and IgA nephropathy (IgAN) are kidney disorders that lead to progressive impairment of filtration. Standard diagnostic markers (creatinine, urea, and eGFR) remain the cornerstone of clinical detection, but they are still insufficient for early diagnosis. Recent studies highlight the potential role of genetic indicators such as CCL2, which are involved in inflammatory signaling and renal tissue injury by attracting monocytes and macrophages into the damaged kidney. This study was designed as a cross-sectional case-control investigation aimed at assessing fold-change expression of CCL2 in the peripheral blood of patients with CKD (n = 30), AKI (n = 10) and IgAN (n = 14), compared with healthy controls (n = 30) after clinical diagnosis of patients with physiological markers. Creatinine, urea and eGFR exhibited highly significant differences between patients and controls, demonstrating strong diagnostic ability (AUC > 0.90 for all markers). Conversely, CCL2 expression showed no significant difference between patient groups and controls, and no significant correlation with physiological markers. Mean CCL2 fold-change were 1.707 in AKI, 1.795 in CKD, and 1.378 in IgAN, indicating only mild elevation without statistical significance. These findings contribute to the evaluation of inflammatory molecular biomarkers in renal diseases by indicating that circulating CCL2 mRNA expression in peripheral blood does not offer additional diagnostic value beyond established physiological markers within this cohort. The results indicate that physiological markers such as creatinine, urea, and eGFR are still good indicators and highlight the limitations of blood-based transcriptional assessment of CCL2 for reflecting renal inflammatory activity, suggesting that tissue-specific or urinary biomarkers may better represent the underlying renal pathological processes. Therefore, blood-based CCL2 in this cohort lacks diagnostic utility, whereas tissue-based or urinary biomarkers could provide enhanced distinction.
Title: Roles of CCL2 Gene Expression in Peripheral Blood of Patients with Kidney Disease
Description:
Chronic kidney disease (CKD), acute kidney injury (AKI), and IgA nephropathy (IgAN) are kidney disorders that lead to progressive impairment of filtration.
Standard diagnostic markers (creatinine, urea, and eGFR) remain the cornerstone of clinical detection, but they are still insufficient for early diagnosis.
Recent studies highlight the potential role of genetic indicators such as CCL2, which are involved in inflammatory signaling and renal tissue injury by attracting monocytes and macrophages into the damaged kidney.
This study was designed as a cross-sectional case-control investigation aimed at assessing fold-change expression of CCL2 in the peripheral blood of patients with CKD (n = 30), AKI (n = 10) and IgAN (n = 14), compared with healthy controls (n = 30) after clinical diagnosis of patients with physiological markers.
Creatinine, urea and eGFR exhibited highly significant differences between patients and controls, demonstrating strong diagnostic ability (AUC > 0.
90 for all markers).
Conversely, CCL2 expression showed no significant difference between patient groups and controls, and no significant correlation with physiological markers.
Mean CCL2 fold-change were 1.
707 in AKI, 1.
795 in CKD, and 1.
378 in IgAN, indicating only mild elevation without statistical significance.
These findings contribute to the evaluation of inflammatory molecular biomarkers in renal diseases by indicating that circulating CCL2 mRNA expression in peripheral blood does not offer additional diagnostic value beyond established physiological markers within this cohort.
The results indicate that physiological markers such as creatinine, urea, and eGFR are still good indicators and highlight the limitations of blood-based transcriptional assessment of CCL2 for reflecting renal inflammatory activity, suggesting that tissue-specific or urinary biomarkers may better represent the underlying renal pathological processes.
Therefore, blood-based CCL2 in this cohort lacks diagnostic utility, whereas tissue-based or urinary biomarkers could provide enhanced distinction.
Related Results
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
BackgroundA clinical dilemma exists in patients with CKD, ESKD, and after kidney transplantation, as they face concurrent risks of both thromboembolic and hemorrhagic complications...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
[RETRACTED] Guardian Blood Balance –Feel the difference Guardian Blood Balance makes! v1
[RETRACTED] Guardian Blood Balance –Feel the difference Guardian Blood Balance makes! v1
[RETRACTED]Guardian Blood Balance Reviews (Works Or Hoax) Does Guardian Botanicals Blood Balance AU Really Works? Read Updated Report! Diabetes and Hypertension is such a health p...
P2Y6 receptor inhibition perturbs CCL2-evoked signalling in human monocytic and peripheral blood mononuclear cells
P2Y6 receptor inhibition perturbs CCL2-evoked signalling in human monocytic and peripheral blood mononuclear cells
The chemokine CCL2 serves to target circulating monocytes and other leukocytes to tissue during innate immune responses and the progression of chronic inflammatory disease via acti...
Three key genes expression profiling in Egyptian rheumatoid arthritis patients
Three key genes expression profiling in Egyptian rheumatoid arthritis patients
Rheumatoid arthritis (RA) is a multi-system autoimmune disease with synovial joints involvement. The triad of autoimmunity, genetics, and environment is the key player in RA pathog...
MicroRNA-204 may predict the renal function in patients with chronic kidney disease
MicroRNA-204 may predict the renal function in patients with chronic kidney disease
Background:
Chronic kidney disease significantly affects human health by loss of excretory kidney function. MicroRNAs have potential predictive and therapeutic signific...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Applying Logistic Regression to Predict Diabetic Nephropathy Based on Some Clinical and Paraclinical Characteristics of Type 2 Diabetic Patients
Applying Logistic Regression to Predict Diabetic Nephropathy Based on Some Clinical and Paraclinical Characteristics of Type 2 Diabetic Patients
Today, the incidence of type 2 diabetes mellitus is increasing rapidly on global. This disease is shown with many complications that significantly affect public health. One of them...

